Biotek-snakken — Oktober 2021
-
Merck stiger efter gode data med covid-behandling i pilleform https://www.proinvestor.com/investornyt/712204/merck-stiger-efter-gode-data-med-covid-behandling-i-pilleform
-
Precigen - melder om positive interim data for fase 1b/2a for AG019 til behandling af type 1 diabetes - https://www.prnewswire.com/news-releases/precigen-actobio-announces-additional-positive-interim-data-from-phase-1b2a-study-of-ag019-actobiotics-a-novel-therapy-designed-to-address-the-underlying-cause-of-type-1-diabetes-301389445.html
-
4 Top Biotech Stocks To Watch In October 2021 https://www.proinvestor.com/investornyt/712584/4-top-biotech-stocks-to-watch-in-october-2021
-
2 Leading Healthcare Stocks to Buy in 2021 and Beyond https://www.proinvestor.com/investornyt/712737/2-leading-healthcare-stocks-to-buy-in-2021-and-beyond
-
Seres : Phase 3 Study Shows SER-109 Associated With Reduction Of ARGs In Patients With Recurrent CDI https://www.proinvestor.com/investornyt/712752/seres-phase-3-study-shows-ser-109-associated-with-reduction-of-args-in-patients-with-recurrent-cdi
-
Nordnet Danmark
Vi har igen samlet den forgangne måneds mest populære værdipapirer, der blandt andet inkluderer to danske biotech selskaber på førstepladsen, både Bavarian Nordic og Evaxion Biotech på henholdsvis den danske og udenlandske liste. Se toplisterne her. https://www.nordnet.dk/blog/september-maaneds-mest-populaere-aktier-investeringsfonde-og-etfer/
-
Orphazyme Now Sees Higher Cash Reserves at End of 2021 https://www.proinvestor.com/investornyt/713478/orphazyme-now-sees-higher-cash-reserves-at-end-of-2021
-
2cureX - Distributionsaftale i Slovenien https://www.proinvestor.com/index.php?p=debat_1&postid=97499
-
AstraZeneca Seeks Emergency Nod In US For AZD7442 To Prevent Symptomatic COVID-19 https://www.proinvestor.com/investornyt/713483/astrazeneca-seeks-emergency-nod-in-us-for-azd7442-to-prevent-symptomatic-covid-19
-
First Patient Dosed In Phase 1b/2 Clinical Trial Of Zanidatamab And Evorpacept (ALX148) In Patients With Advanced HER2-Expressing Breast Cancer And Other Solid Tumors https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-and-alx-oncology-announce-first-patient-dosed-phase/
-
XBRANE BIOPHARMA AND AGC BIOLOGICS ENTER INTO AN AGREEMENT TO MANUFACTURE XCIMZANE
FOR CLINICAL DEVELOPMENT https://xbrane.com/en/mfn_news_en/xbrane-biopharma-and-agc-biologics-enter-into-an-agreement-to-manufacture-xcimzane-for-clinical-development/ -
XBrane…ufatteligt den falder på en ny partner aftale?? Alt kører efter planen og breakeven i slutningen af 2023/start 2024….pengekassen er fyldt til breakeven….hvad er problemet?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind